Plug-and-Play Technology

Electron Microscope Image of GEM particle
Electron Microscope Image of two GEM particles

Our proprietary technology exploits the innate and adaptive immune system to engage disease-causing pathogens at their port of entry, the mucosal layers of the body. Uniquely, our technology is build on particles that not only elicit a strong and robust systemic immune response, but also a strong local immune response in mucosal layers in the nose, airways, gut and other places in the body. The particles provide a safe and versatile backbone that can efficiently be loaded with a wide variety of antigens from viral, bacterial and parasitic pathogens, thereby mimicking the pathogenic entity.

31.05.10 Mucosis receives financial support from the Dutch government for its FluGEM program
more >

27.04.10 Mucosis appoints Dr. Roberto Grimandi as chief medical officer
more >

22.09.09 Mucosis receives key US patent covering its Mimopath™ technology
more >

28.01.09 Mucosis B.V. and PATH start development of pneumococcal vaccines
more >

15.12.08 Mucosis B.V. and TNO announce flu vaccine research and development partnership.
more >

10.12.07 News article in “Het Financieele Dagblad”.
more >

06.11.08 Mucosis B.V. appoints Dr. Govert Schouten as CEO. more >

10.09.07 Mucosis raises € 3 million in first financing round more >